Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches

被引：0
作者：
Dyfrig Hughes
Joanna Charles
Dalia Dawoud
Rhiannon Tudor Edwards
Emily Holmes
Carys Jones
Paul Parham
Catrin Plumpton
Colin Ridyard
Huw Lloyd-Williams
Eifiona Wood
Seow Tien Yeo
机构：
[1] Ardudwy,Centre for Health Economics and Medicines Evaluation
[2] Bangor University,Clinical Pharmacy Department, Faculty of Pharmacy
[3] Cairo University,Department of Public Health and Policy, Faculty of Health and Life Sciences
[4] University of Liverpool,undefined
来源：
PharmacoEconomics | 2016年 / 34卷
关键词：
Economic Evaluation; Discrete Choice Experiment; Multinational Trial; Randomise Control Trial Data; General Practitioner Record;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Trial-based economic evaluations are an important aspect of health technology assessment. The availability of patient-level data coupled with unbiased estimates of clinical outcomes means that randomised controlled trials are effective vehicles for the generation of economic data. However there are methodological challenges to trial-based evaluations, including the collection of reliable data on resource use and cost, choice of health outcome measure, calculating minimally important differences, dealing with missing data, extrapolating outcomes and costs over time and the analysis of multinational trials. This review focuses on the state of the art of selective elements regarding the design, conduct, analysis and reporting of trial-based economic evaluations. The limitations of existing approaches are detailed and novel methods introduced. The review is internationally relevant but with a focus towards practice in the UK.
引用
收藏
页码：447 / 461
页数：14
相关论文
共 233 条
  • [1] Sculpher MJ(2006)Whither trial-based economic evaluation for health care decision making? Health Econ 15 677-687
  • [2] Claxton K(2011)Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting BMJ 342 d1548-172
  • [3] Drummond M(2015)Cost-effectiveness analysis alongside clinical trials II. An ISPOR Good Research Practices Task Force report Value Health. 18 161-872
  • [4] McCabe C(2010)Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program Value Health. 13 867-104
  • [5] Petrou S(2012)Cost-minimisation analysis of endometrial thermal ablation in a day case or outpatient setting under different anaesthesia regimens Eur J Obstet Gynecol Reprod Biol 162 102-107
  • [6] Gray A(2003)Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada’s Working Group on Economic Analysis Chronic Dis Can. 24 102-703
  • [7] Ramsey SD(2005)Incorporating pharmacoeconomic and health outcomes into randomized clinical trials Expert Rev Pharmacoecon Outcomes Res. 5 695-S20
  • [8] Willke RJ(2009)Design and analysis issues for economic analysis alongside clinical trials Med Care 47 S14-141
  • [9] Glick H(2001)Design issues for conducting cost-effectiveness analyses alongside clinical trials Annu Rev Public Health 22 129-220
  • [10] Reed SD(2012)Statistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisal Med Decis Mak 32 209-271
12345678910